Can Molecular and Cellular Neuroprotection Be Translated Into Therapies for Patients? | Zendy

Michael Tymianski | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Can Molecular and Cellular Neuroprotection Be Translated Into Therapies for Patients?

Author(s) -

Michael Tymianski

Publication year - 2010

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.110.595496

Subject(s) - neuroprotection , medicine , stroke (engine) , clinical trial , translational research , preclinical research , neuroscience , intensive care medicine , bench to bedside , acute stroke , stroke recovery , bioinformatics , pharmacology , rehabilitation , physical therapy , psychiatry , medical physics , pathology , psychology , mechanical engineering , emergency department , engineering , biology

The concept of neuroprotection is based on sound scientific data derived in preclinical studies. However, candidate neuroprotectants have never been successfully translated to patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research